LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives $110.60 Average Price Target from Analysts

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) have received a consensus rating of “Hold” from the nine research firms that are covering the stock, MarketBeat.com reports. Six equities research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $110.60.

A number of equities research analysts have recently weighed in on the company. Barrington Research lowered LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Wednesday, August 5th. Wells Fargo & Company reduced their price target on LeMaitre Vascular from $104.00 to $94.00 and set an “equal weight” rating on the stock in a research report on Wednesday, August 5th. Citigroup reaffirmed a “market outperform” rating on shares of LeMaitre Vascular in a research note on Tuesday, July 21st. Weiss Ratings downgraded LeMaitre Vascular from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Friday, August 14th. Finally, Wall Street Zen lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st.

Hedge Funds Weigh In On LeMaitre Vascular

Several large investors have recently made changes to their positions in the business. Tidal Investments LLC bought a new position in shares of LeMaitre Vascular in the 2nd quarter valued at approximately $526,000. Engineers Gate Manager LP boosted its holdings in LeMaitre Vascular by 38.4% during the second quarter. Engineers Gate Manager LP now owns 14,008 shares of the medical instruments supplier’s stock valued at $1,344,000 after acquiring an additional 3,888 shares during the period. Nykredit A S acquired a new stake in LeMaitre Vascular in the 2nd quarter valued at approximately $82,000. Corient Private Wealth LP raised its stake in LeMaitre Vascular by 62.8% during the 2nd quarter. Corient Private Wealth LP now owns 25,589 shares of the medical instruments supplier’s stock valued at $2,456,000 after purchasing an additional 9,875 shares during the last quarter. Finally, Grandeur Peak Global Advisors LLC lifted its stake in shares of LeMaitre Vascular by 63.1% in the second quarter. Grandeur Peak Global Advisors LLC now owns 161,010 shares of the medical instruments supplier’s stock valued at $15,451,000 after buying an additional 62,287 shares during the period. 84.64% of the stock is currently owned by hedge funds and other institutional investors.

LeMaitre Vascular Stock Up 2.2%

LMAT stock opened at $80.98 on Friday. The stock has a 50-day simple moving average of $86.84 and a two-hundred day simple moving average of $97.61. LeMaitre Vascular has a twelve month low of $78.22 and a twelve month high of $118.01. The firm has a market capitalization of $1.85 billion, a PE ratio of 28.41, a PEG ratio of 2.28 and a beta of 0.50. The company has a quick ratio of 13.96, a current ratio of 16.31 and a debt-to-equity ratio of 0.40.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Tuesday, August 4th. The medical instruments supplier reported $0.74 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.81 by ($0.07). The business had revenue of $70.38 million during the quarter, compared to analysts’ expectations of $71.47 million. LeMaitre Vascular had a return on equity of 15.63% and a net margin of 25.02%.The company’s quarterly revenue was up 9.6% on a year-over-year basis. During the same quarter last year, the business posted $0.60 EPS. On average, equities analysts predict that LeMaitre Vascular will post 2.89 EPS for the current fiscal year.

LeMaitre Vascular Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 3rd. Shareholders of record on Thursday, August 20th were given a dividend of $0.25 per share. The ex-dividend date of this dividend was Thursday, August 20th. This represents a $1.00 annualized dividend and a yield of 1.2%. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 35.09%.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures and markets medical devices used primarily in the treatment of peripheral vascular disease. Its products are designed for vascular surgeons and other specialists performing procedures on arteries and veins outside the heart and brain.

The company’s portfolio includes biologic and synthetic vascular grafts, thrombectomy catheters, angioplasty balloons, valvulotomes, vascular shunts, vessel-closure devices and other surgical instruments. LeMaitre also offers products used in vessel preparation, plaque removal and the repair or replacement of diseased blood vessels.

Founded in 1983 and headquartered in Burlington, Massachusetts, LeMaitre Vascular serves customers in the United States and international markets.